Table 2 Long-term outcome after median 9 years in comparison with trial data of 61 juvenile idiopathic arthritis patients who participated in a randomised placebo-controlled sulfasalazine trial13*
VariableTrial baselineEnd of trial (24 weeks)Follow-up (median 9 years)Differences between end of trial and follow-up p value
General assessments
    Active joints (range 0 to 71)5 (3 to 11)2 (1 to 7)2 (0 to 6)NS
    Limited joints (range 0 to 67)†4 (1 to 7)2 (1 to 5)5 (2 to 12)<0.001
    Physician’s score of disease activity (range 0 to 5)‡3 (3 to 4)2 (1 to 3)2 (1 to 3)NS
    Erythrocyte sedimentation rate mm/h27 (11 to 43)11 (6 to 22)8 (5 to 22)NS
    C-reactive protein mg/l6 (1 to 29)2 (1 to 11)2 (1 to 6)NS
No. (%) of patients with
    No active joints014 (23%)16 (26%)NS
    No limited joints6 (10%)9 (15%)6 (10%)NS
    >4 active joints36 (59%)20 (33%)18 (30%)NS
    >4 limited joints26 (43%)18 (30%)33 (54%)<0.001
  • *Values are given in median and interquartile range (IQR 25 to 75%) or number and percentage as indicated; †limited joints = joints with limitation in range of motion;17 ‡PGAS: 0 = none; 1+ = very low; 2+ = low; 3+ = moderate; 4+ = active; 5+ = very active.